PCOS Renamed PMOS to Address Decades of Misdiagnosis
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- PCOS was renamed PMOS about two months ago to better capture its endocrine, metabolic, cardiovascular, and mental health impacts and to leave room for a possible male form, according to Helena Teede, a women's health professor at Monash University in Australia who helped reassess the condition.
- Women of color experience double the prevalence of PMOS compared to white women and often go undiagnosed; Black women face more severe hirsutism and hypertension, while Hispanic and Latina women face more severe metabolic complications, and both groups face elevated risk for diabetes, preeclampsia, and mood disorders.
- More than 5 million women and girls of reproductive age in the US live with PMOS, and the World Health Organization estimates up to 70% of people with the condition remain undiagnosed worldwide.
- The old name drove clinical misdiagnosis: only about 25% of patients actually present with extra ovarian follicles, yet more than one-third of physicians in one survey still associated "cysts on ovaries" with the syndrome, according to Margaret Lippincott, director of the Multidisciplinary Care Center for PMOS at Massachusetts General Hospital.
- Andrea Medina-Alvarado of the National Latina Institute for Reproductive Justice warned that the One Big Beautiful Bill Act is expected to strip millions of Medicaid access next year while ICE raids are deterring Latino communities from seeking groceries, work, or health care.
- Dietitian Alexis Brooks noted that "lean PMOS" patients are also dismissed because physicians won't consider the diagnosis in women outside the larger-body stereotype — even though, as Lippincott stressed, obesity is not and has never been part of the diagnostic criteria.
Why it matters: The rename confronts a structural diagnostic failure built into the condition's old name: it pointed doctors toward ovarian cysts absent in roughly 75% of patients, delaying care for millions. With Black and Latina women facing compounded barriers — higher prevalence, more severe symptoms, looming Medicaid losses, and immigration-related avoidance of health care — the cost of decades of mislabeling has fallen hardest on those least equipped to push back.
Ask SkimNews
